The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–
directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …

Light chain cast nephropathy (LCCN) is a leading cause of acute kidney injury (AKI) in
patients with multiple myeloma (MM) and is now defined as a myeloma defining event. While …

For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care
includes induction therapy followed by autologous stem cell transplantation (ASCT) …